Articles tagged "Immunosuppression"

2019 American Transplant Congress
Early Diagnosis of BK Virus Nephropathy Can Retrieve Kidney Allografts by Simple Reduction in Immunosuppressive Agents
N. Iwahara, D. Iwami, K. Hotta, H. Okada, N. Shinohara
Hokkaido Univercity, Sapporo, Japan
*Purpose: Although BK virus nephropathy (BKVN) is a major complication after kidney transplant leading to graft loss, it is often difficult to diagnose and treat.…
2019 American Transplant Congress
The Immunomodulatory Role of Type I Interferons in Alloimmunity
I. Sulkaj, H. Allos, S. K. Eskandari, J. M. Safadi, J. Y. Choi, B. S. Al Dulaijan, E. Al-Hussain, S. Cai, J. R. Azzi
Medicine, Brigham and Women's Hospital, Boston, MA
*Purpose: Despite a growing body of work on type 1 interferon (IFNAR1) signaling, there is a lack of consensus on the immunological properties of type…
2019 American Transplant Congress
Genome-Wide Profiling of BK Polyomavirus Integration in Urothelial Carcinoma of Kidney Transplant Recipients Reveals a Potential Microhomology or Nonhomologous End Joining Mediated Integration Mechanism
Y. Jin¹, Y. Zhou¹, W. Deng¹, R. Lee², Y. Liu¹, M. Blute³, R. Liu¹, N. Elias⁴, F. Fu¹, B. Guan¹, J. Geng¹, J. Ma⁵, J. Zhou⁵, N. Liu⁵, C. Wu⁶, Y. Miao¹
¹Nanfang Hospital, Southern Medical University, Guangdzhou, China, ²Departments of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Departments of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Departments of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Mygenostics Co., Beijing, China, ⁶Departments of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
*Purpose: Chronic BK polyomavirus (BKV) infection is recognized as a potential oncogenic factor of urothelial carcinoma (UC) in renal transplant recipients. Besides, a positive correlation…
2019 American Transplant Congress
Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study
H. Tedesco Silva¹, F. Citterio¹, M. Henry¹, T. R. Srinivas¹, Y. Watarai¹, S. Steinberg¹, N. Basic-Jukic¹, V. D. Garcia¹, E. Mor¹, V. R. Peddi¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², J. Pascual¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: To compare the antirejection efficacy outcomes of an everolimus+reduced-exposure CNI (EVR+rCNI) vs mycophenolic acid+standard-exposure CNI (MPA+sCNI) regimen in renal transplant recipients (RTxRs) from the…
2019 American Transplant Congress
A Prospective Randomized Multicenter Trial (B E S T Trial) of Belatacept-Based C N I- and Corticosteroid-Free Immunosuppression: Final Two Year Results
D. B. Kaufman¹, A. R. Shields², J. P. Leone³, A. Wiseman⁴, A. J. Matas⁵, P. West-Thielke⁶, J. Lipscomb², E. King², R. R. Alloway⁷, E. S. Woodle for the BEST Study Group²
¹University of Wisconsin, Madison, WI, ²University of Cincinnati, Cincinnati, OH, ³Tampa General, Tampa, FL, ⁴University of Colorado School of Medicine, Denver, CO, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Illinois, Chicago, Chicago, IL, ⁷University of Cincinnati, Cincinnati, WI
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal Trial) is a prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based calcineurin inhibitor-free (CNI), early…
2019 American Transplant Congress
Patient Centered AUC-Monitoring of Tacrolimus Using Capillary Microsampling
M. T. Gustavsen, K. Midtvedt, N. Vethe, S. Bergan, A. Åsberg
Oslo University Hospital, Rikshospitalet, Oslo, Norway
*Purpose: To reduce unwanted side effects of Tacrolimus (Tac), improvement of dosing is warranted. Therapeutic drug monitoring (TDM) of Tac based on trough concentrations (C0)…
2019 American Transplant Congress
Soluble C Type Lectin Receptor Protein Inhibition of Natural Killer Cell Mediated Tubular Epithelial Cell Death
S. Balaji¹, B. Fuhrmann², D. Lian³, H. Diao³, S. Ma³, Z. Zhang³, A. M. Jevnikar³
¹Physiology, Western University, London, ON, Canada, ²Microbiology and Immunology, Western University, London, ON, Canada, ³London Health Sciences Centre, London, ON, Canada
*Purpose: We have previously shown that Natural Killer (NK) cells can mediate kidney tubular epithelial cell (TEC) death and kidney ischemia-reperfusion injury (IRI) as well…
2019 American Transplant Congress
Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population
B. Valdepenas, J. Benken, E. Benedetti, Z. Hajjiri, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Conversion to belatacept as maintenance immunosuppression has gained traction to prevent calcineurin inhibitor (CNI) induced toxicities in renal transplant (RTx) recipients. However, limited knowledge…
2019 American Transplant Congress
Risk Factors for Initial Sub- and Supra-Therapeutic Tacrolimus Trough Levels in Renal Transplant Recipients
M. Kapugi, K. Cunningham, C. D'Agostino, C. Kane, A. Novak, J. Schulte
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Sub-therapeutic tacrolimus trough levels have been associated with increased risk of rejection in renal transplant recipients and supra-therapeutic levels with infectious risks and drug…
2019 American Transplant Congress
Thymoglobulin Versus Alemtuzumab Induction in High Immunologic Risk Kidney Transplants
J. Lockridge¹, J. Pryor¹, D. Norman¹, A. Olyaei²
¹OHSU, Portland, OR, ²Pharmacy, OHSU, Portland, OR
*Purpose: The optimal induction immunosuppressive therapy to prevent kidney transplant rejection remains controversial, specifically among high immunologic risk patients. Our aim was to compare the…